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Abstract Elevated erythrocyte destruction in sickle cell
disease (SCD) results in chronic hyperbilirubinaemia and,
in a subset of patients, cholelithiasis occurs. We investi-
gated whether the (TA)n promoter polymorphism in the
UDP-glucuronosyltransferase 1A1 gene (UGT1A1) may
modify bilirubin metabolism, influencing bilirubinaemia,
predisposition to cholelithiasis and subsequent cholecys-
tectomy, in a group of 153 young SCD patients (mean age
12.0 ± 9.0 years) predominantly of Bantu beta S haplo-
type. The concomitant effect of alpha thalassaemia was also
analysed. Among the several UGT1A1 genotypes found, the
most frequent were the (TA)6/(TA)6 (n = 37), (TA)6/(TA)7
(n = 60) and (TA)7/(TA)7 (n = 29). These groups of
patients did not significantly differ in age, gender ratio and
haemoglobin, foetal haemoglobin and reticulocyte levels.
On the other hand, total bilirubin levels were significantly
different between groups, with an increased (TA) repeat
number being associated with higher bilirubinaemia. Fur-
thermore, both cholelithiasis and cholecystectomy were
more frequent in groups with higher (TA) repeat number,
although the former association was not statistically sig-
nificant. None of the mentioned parameters is statistically
different within UGT1A1 groups with the presence of alpha
thalassaemia. Thus, the UGT1A1 promoter polymorphism
may represent an important nonglobin genetic modifier of
Bantu SCD patients’ clinical manifestations, even at a
young age.
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Introduction
Sickle cell disease (SCD; OMIM #603903) is the most
common genetic abnormality affecting people of African
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ancestry. It is caused by a molecular defect in the hae-
moglobin (Hb) beta (b)-chain, where valine is substituted
for glutamic acid in the sixth amino acid position. The
resulting variant is called Hb S as opposed to the normal
adult Hb A. The polymerisation of deoxygenated Hb S is
the primary event in the molecular pathogenesis of SCD,
resulting in a distortion of the red cell shape and a marked
decrease in its deformability. SCD is characterised by a
chronic haemolytic anaemia and recurrent vasoocclusive
episodes, leading to multisystemic complications with a
wide variation in severity (Serjeant 2001). Part of this
clinical heterogeneity can be explained by the coinheri-
tance of genetic modifiers linked or nonlinked to the globin
gene clusters (Steinberg and Adewoye 2006).
It is known that the accelerated erythrocyte destruction
in SCD often leads to chronic hyperbilirubinaemia, as
bilirubin catabolism is the final step in the breakdown
of haem from haemoglobin. Consequently, some clinical
complications, such as cholelithiasis, recurrent painful
abdominal events and cholecystitis are frequent in this
pathology.
The primary bilirubin-catabolising hepatic enzyme,
UDP-glucuronosyltransferase 1A1 (UGT1A1; Chr 2q37;
EC 2.4.1.17), mediates the conjugation of bilirubin into a
water-soluble conjugated form that is excreted in the bile.
The UGT1A1 promoter contains an A(TA)nTAA sequence
with a common (TA)6 tandem repeat. The homozygosity
for the (TA)7 repeat has been associated with decreased
enzyme function and Gilbert’s syndrome of unconjugated
hyperbilirubinaemia (Monaghan et al 1996). Other alleles,
a shorter (TA)5 and a longer (TA)8, have been described in
people of African descent (Beutler et al. 1998). Choleli-
thiasis, by promoting cholecystitis, is responsible for high
levels of morbidity in SCD patients, and elective chole-
cystectomy is therefore recommended for patients
developing this complication.
The aim of this study was to determine whether the
promoter UGT1A1 polymorphism (resulting in UGT1A1
activity variation) could modify bilirubin metabolism
and affect serum bilirubin concentration in young SCD
patients, thereby influencing the development of choleli-
thiasis and subsequently cholecystectomy. Also, the effect
of alpha thalassaemia (a-thalassaemia) within UGT1A1
genotype groups was investigated.
Patients and methods
This study was performed on 153 young Portuguese SCD
patients (mean age 12.0 ± 9.0 years), the majority descend-
ing from African immigrants (preponderantly from Angola,
Sao Tome and Principe and Cape Verde). All patients, or
their legal representatives, gave informed consent prior to
their inclusion in the study. SCD steady-state patient data,
concerning haemoglobin, foetal haemoglobin, reticulocytes
and total bilirubin levels (determined by standard proce-
dures) were averaged for each patient, and clinical
information was gathered for cholelithiasis (detected by
liver/biliary ultrasound scans) and cholecystectomy. Geno-
mic DNA was extracted from peripheral blood leukocytes
by a salting-out procedure (Miller et al 1988). The homo-
zygosity for the SCD mutation was confirmed by a
bidirectional allele-specific polymerase chain reaction
(PCR) as described (Liu et al. 1997). The number of (TA)
repeats in the UGT1A1 promoter was analysed by a
PCR-based methodology using the primers described by
Monaghan et al. (1996) in which the sense primer was 5-
carboxyfluorescein (FAM) fluorescent-tagged. One aliquot
of each PCR product was analysed by Gene Scan 3.7
software, along with a molecular weight marker.
Beta globin (b-globin) gene-cluster haplotypes were
assigned after examining nine restriction endonuclease
sites within the cluster [Hinc II (e), Xmn I (50 to Gc), Hind
III (within Gc and Ac), Hinc II (within and 30 to wb), Hinf I
(50 to b), Ava II (within b), and Hinf I (3’ to b)]. Aliquots
of the amplified products were digested with the appro-
priate restriction enzymes under the conditions recom-
mended by the manufacturer. Haplotypes were established
by determining the presence or absence of cleavage at each
site and by compiling the results into one pattern classified
according to Orkin et al. (1982). The allelic phase was
determined by family studies whenever necessary. The
-a3.7 kb deletion was searched for by gap PCR, as pre-
viously described (Dode´ et al. 1992). Individuals were
scored according to the presence/absence of deletional
alleles. In order to perform statistical analyses, SCD
patients presenting one or two deletional (-a3.7) alleles
were integrated in the same group, named a-thal (see
Table 3).
All statistical analyses were performed using the sta-
tistical software package SPSS 14.0. The significance of
the differences between groups of patients was assessed
using the Kruskal–Wallis, chi-square, analysis of variance
(ANOVA), Wald, Mann–Whitney U or Fisher’s exact tests,
as appropriate. The odds ratios (OR) were obtained by
applying a logistic regression model using the UGT1A1
genotype as the independent variable and the cholelithiasis
and cholecystectomy as dependent variables. The reference
class was the 6/6 UGT1A1 genotype. Significance for sta-
tistical analysis was defined as a P \ 0.05.
Results
The homozygosity for the sickle cell mutation
(HBB:c.20A [ T) was confirmed in all patients. The
J Hum Genet (2008) 53:524–528 525
123
UGT1A1 PCR fragments obtained ranged between 96 and
102 bp, which corresponded to a (TA)5–8 variation. Con-
sequently, several UGT1A1 genotypes were found: 5/5
(n = 1); 5/6 (n = 9); 5/7 (n = 5); 5/8 (n = 3); 6/6
(n = 37); 6/7 (n = 60); 6/8 (n = 6); 7/7 (n = 29) and (7/
8) (n = 3); (Appendix 1 of Supplementary Material). Only
patients belonging to the three largest genotype groups
(namely, 6/6, 6/7 and 7/7) were considered for statistical
analyses. Comparisons performed for these three groups of
patients did not reveal any significant difference concern-
ing age, gender ratio, and Hb, Hb F and reticulocyte levels,
which denotes a similar degree of haemolysis between
groups. However, total bilirubin levels were significantly
different between groups (P = 0.003; Kruskal–Wallis test),
with an increased (TA) repeat number being associated
with higher bilirubinaemia (Table 1).
The chi-square tests used for cholelithiasis and chole-
cystectomy data showed that both cholelithiasis (P =
0.407) and cholecystectomy (P = 0.016) were increased
in the patients with higher (TA) repeat number, although
the former difference was not statistically significant
(Table 1). The OR of having cholelithiasis for genotypes
6/7 [OR = 1.500; 95% confidence interval (CI) = 0.595–
3.784) and 7/7 (OR = 2.057; 95% CI = 0.708–5.980] was
increased when compared with 6/6. The same comparison
for cholecystectomy revealed an increased risk only for
genotype 7/7 (OR = 4.714; 95% CI = 0.869–25.581)
(Table 2).
To gain further insight into the modifying effect of
UGT1A1 polymorphism, the bS haplotype and the a-globin
genotype were determined in our SCD patients. The
prevalence of the Bantu haplotype was similar among the
three UGT1A1 groups (Bantu allelic frequency in the 6/6
UGT1A1 group was 73.0%; in the 6/7 group 62.3%; and in
the 7/7 group 67.2%; P = 0.305). The overall a-thalassae-
mia (-a3.7) allelic frequency was 26% and was not
significantly different between UGT1A1 genotype groups.
We found that in young SCD patients predominantly of
Bantu bS haplotype, the coinheritance of a-thalassaemia
did not significantly influence the level, total bilirubin
level, cholelithogenesis and the need for cholecystectomy
(Table 3).
Phenotype features of patients belonging to the less
frequent genotype groups are summarised in Appendix 1 of
Supplementary Material.
Discussion
In this study, we investigated the genetic architecture of a
young population with a SCD subphenotype characterised
by hyperbilirubinaemia and cholelithiasis. The (TA) repeat
number found within the UGT1A1 gene promoter varied
between 5 and 8, which was expected due to the African
ancestry of this population (Beutler et al. 1998).
The coinheritance of Gilbert’s syndrome determinant
and genetic alterations associated with disorders that
increase turnover of red blood cells or their precursors has
been reported to elevate bilirubin levels, e.g. in b-thalas-
saemia (Galanello et al. 1997, 1999b), G6PD deficiency
(Galanello et al. 1999a) and SCD (Adekile et al. 2005;
Chaar et al. 2005; Fertrin et al. 2003; Harverfield et al.
2005; Passon et al. 2001). In fact, in addition to the results
presented here, the mentioned studies performed in SCD
Table 1 Comparison of sickle cell disease phenotype features in
patients stratified according to UGT1A1 genotype
UGT1A1 genotype
6/6 6/7 7/7
Number 37 60 29
Age (years) 12.9 ± 8.6 9.0 ± 7.4 12.7 ± 9.0
P* 0.580
Gender ratio (M/F) 18/19 30/30 14/15
P** 0.985
Haemoglobin (g/dl) 7.88 ± 0.92 7.93 ± 1.37 8.40 ± 1.11
P*** 0.398
Haemoglobin F (%) 8.33 ± 5.27 10.03 ± 6.39 8.46 ± 5.19
P* 0.535
Reticulocytes (%) 10.21 ± 3.98 11.61 ± 6.93 11.70 ± 4.58
P* 0.500
Total bilirubin (mg/dl) 2.55 ± 1.78 3.20 ± 3.14 4.67 ± 3.67
P* 0.003
Cholelithiasis (%) 29.4 38.5 46.2
P** 0.407
Cholecystectomy (%) 5.7 3.8 22.2
P** 0.016
* Kruskal–Wallis test
** Chi-square test
*** Analysis of variance test
Table 2 Calculation of odds ratios between UGT1A1 genotype
groups
UGT1A1 genotype Odds ratios
6/6–6/7 6/6–7/7
Cholelithiasis 1.500 2.057
95% CI 0.595–3.784 0.708–5.980
P* 0.390 0.185
Cholecystectomy 0.647 4.714
95% CI 0.087–4.821 0.869–25.581
P* 0.671 0.072
CI confidence interval
* Wald test
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patients have shown that homozygosity for the (TA)7
UGT1A1 genotype significantly influences bilirubin
metabolism and is associated with higher steady-state
concentrations of unconjugated serum bilirubin. At least in
our case, this fact could not be explained by increased
haemolysis, as there are no significant differences in
average Hb concentration and in reticulocyte count among
the different UGT1A1 genotype groups (Table 1). Some
other studies were performed regarding the influence of the
UGT1A1 polymorphism on cholelithiasis, but the associa-
tion has been less consistent that with a more proximal
phenotype, namely, hyperbilirubinaemia. Moreover, age
has been considered a modifier of UGT1A1 polymorphism
influence. As an example, Harverfield et al. (2005)
observed that the (TA)7 homozygosity is a significant risk
factor for cholelithiasis development only in older SCD
patients (34.6 ± 10.9 years) but not in a younger adult
cohort group (25.0 ± 2.9 years). Although gallstones were
identified at a mean age of 15.1 years in 40.6% of this
cohort group, there was no association with UGT1A1 (TA)n
genotypes (Harverfield et al. 2005). On the other hand,
Fertrin et al. (2003) analysed a group of adult SCD patients
(28.5 ± 10.7 years) and observed that although the fre-
quency of cholelithiasis was higher in patients with the 7/7
genotype, the difference was not statistically significant
(Fertrin et al. 2003). Considering the need for cholecys-
tectomy, the difference between 6/7 and 6/6 patients was
statistically significant, although the difference between the
other groups was not (Fertrin et al. 2003). Furthermore, in
studies performed in SCD children (3–19 years) the
development of symptomatic cholelithiasis requiring cho-
lecystectomy was significantly higher for children with the
7/7 genotype than those with the 6/7 or 6/6 genotypes
(Passon et al. 2001). Finally, Chaar et al. (2005) observed
that the frequency of cholelithiasis was significantly higher
in an SCD group of children having 7/7 or 7/8 genotype.
On the whole, analysing our results along with previously
published data, we can conclude that the UGT1A1 pro-
moter genotype is unquestionably an important genetic
determinant of hyperbilirubinaemia in SCD. However, its
influence on cholelithiasis development is not so straight-
forward and seems to be modulated by other factors,
among which age is relevant. Concerning patients who
need cholecystectomy, their inclusion in the 7/7 genotype
group is remarkable, thereby confirming the penetrance of
this genotype.
It is known that the coinheritance of a-thalassaemia and
SCD determinants reduces the mean corpuscular haemo-
globin concentration of red blood cells, which tends to
inhibit sickling. It was observed that the coexistence of a-
thalassaemia decreases the chance of developing gallstones
in Arab Indian haplotype SCD patients, which may be
related to lower haemolysis, as suggested by their predis-
position to present, in general, higher mean Hb levels
(Haider et al. 1998). In addition, Adekile et al. (2005)
observed that the b-globin haplotype and the coexisting a-
thalassaemia did not have significant influence on serum
bilirubin levels in Arab Indian haplotype SCD patients
(Adekile et al. 2005). Furthermore, Chaar et al. (2006)
showed that although a-thalassaemia is associated with a
modest reduction in haemolysis and unconjugated bilirubin
level, UGT1A1 polymorphism outweighs its effect on
cholelithogenesis in SCD patients predominantly of Benim
bS haplotype (Chaar et al. 2006). Vasavda et al. (2007) also
observed that a-thalassaemia was significantly associated
with reduced bilirubin levels in SCD adult patients. In
our young SCD patient series predominantly of Bantu
bS haplotype, we found that the coinheritance of
Table 3 Influence of a-
thalassaemia (a-thal.) on
bilirubin-associated parameters
among UGT1A1 genotype
groups
* Mann–Whitney test
** Fisher’s exact test
UGT1A1 genotype groups
6/6 6/7 7/7
Number aa/aa 19 36 14
a-thal. 18 24 15
Haemoglobin (g/dl) aa/aa 7.59 ± 0.87 8.09 ± 1.46 7.70 ± 0.84
a-thal. 8.14 ± 1.08 7.87 ± 0.93 8.35 ± 1.05
P* 0.192 0.389 0.155
Total bilirubin (mg/dl) aa/aa 2.80 ± 2.45 3.61 ± 3.75 5.42 ± 4.94
a-thal. 2.79 ± 2.41 2.51 ± 1.53 3.98 ± 1.84
P* 0.961 0.205 0.793
Cholelithiasis (%) aa/aa 29.4 41.2 58.3
a-thal. 29.4 36.8 35.7
P** 1.000 1.000 0.431
Cholecystectomy (%) aa/aa 11.8 5.7 30.8
a-thal. 0.00 0.00 14.3
P** 0.229 0.535 0.385
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a-thalassaemia does not significantly influence Hb level,
total bilirubin level, cholelithogenesis and the need for
cholecystectomy (Table 3). However, we observed that the
coinheritance of a-thalassaemia is slightly associated with
a positive effect on the mentioned parameters, mainly in
the 7/7 genotype group in which patients presented higher
haemoglobin level, lower bilirubin, fewer cholelithiasis
and undergo cholecystectomy less frequently.
In conclusion, our study, the first performed regarding
young Bantu SCD patients, reinforces the concept that the
sickle cell mutation alone is not sufficient to explain the
wide range of phenotypic expression characteristic of SCD.
Our results attribute to UGT1A1 promoter polymorphism
an important modifying effect of the clinical manifestations
in Bantu SCD patients, namely, in bilirubin metabolism,
cholelithiasis development and the need for cholecystec-
tomy, even at a young age. Also, we observed that in these
patients, the modulating effect of the UGT1A1 promoter
polymorphism is not significantly altered by the coinheri-
tance of a-thalassaemia determinants.
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